EGFR and glioblastoma: For example, a team from Sirnaomics Inc. investigated a siRNA cocktail NP (STP‐523) with multiple targets EGFR, VEGF, and AGT encoding O6‐mehtylguanine‐DNA‐methlytransferase for treatment of GBM, and observed enhanced treatment effect compared to the single gene‐targeted siRNA inhibitors.